Passage: Laga soo bilaabo 2019, laba iyo toban daawo oo wax ka beddelaya cudurka ayaa oggolaaday hay'adaha sharciyeynta ee cudurka sclerosis badan ee soo noqnoqda (RRMS). Waxay yihiin interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, iyo cladribine. Waxtarkooda kharashka ee 2012 ma cadda. Bishii Maarso 2017 FDA waxay ansixisay ocrelizumab, oo ah anti-CD20 monoclonal antibody, oo ah daaweyn loogu talagalay RRMS, oo leh shuruudo dhowr ah tijaabooyinka wajiga IV. In RRMS, waxay si dhexdhexaad ah u yareeyaan tirada weerarada. Daawooyinka interferon beta-1a iyo glatiramer acetate ayaa weli hoos u dhacaya oo si cad u hoos u dhacaya, si kastaba ha noqotee, daawooyinka kale ee loo isticmaalo si loo daaweeyo dhibaatooyinka daran
interferon beta-1a